Therapeutic Treatment Plan Optimization during the COVID-19 Pandemic: A Comprehensive Physicochemical Compatibility Study of Intensive Care Units Selected Drugs.

LC stability-indicating assay method SARS-CoV-2 pandemic compatibility study degradation kinetic drugs mixtures (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine) intensive care units

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
28 Feb 2022
Historique:
received: 17 01 2022
revised: 25 02 2022
accepted: 25 02 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 27 3 2022
Statut: epublish

Résumé

The SARS-CoV-2 pandemic has resulted in a dramatic rise of the demand for medical devices and drugs. In this context, an important shortage of programmable syringe pumps, used to administrate different drugs in intensive care units, was seen. The opportunity of administrating combinations of five intensive care units selected drugs (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine) was considered. The drug mixtures were studied in a pure form or diluted in NaCl 0.9% or G5%. Twenty-six possible combinations of the five drugs were produced in glass vials or polypropylene syringes and stored at 25 °C for 14 days. The LC method was implemented to study drugs combinations in the presence of the degradation products. The clearness and pH were also monitored. All the 26 possible combinations displayed adequate physicochemical stability at 25 °C: at least 3 days and 7 days, respectively, for the dilution in 0.9% NaCl or glucose 5%, and the pure drug products mixtures. The study provided sufficient stability results, covering the medication administration period of at least three days. The combination of more than two drugs offers the advantage of minimizing the individual doses and reduces unwanted side-effects. Hence, this study opens up the possibility of combining the five drugs in one single syringe, which is useful especially under the current circumstances associated with an important shortage of programmable syringe pumps and pharmaceuticals.

Sections du résumé

BACKGROUND BACKGROUND
The SARS-CoV-2 pandemic has resulted in a dramatic rise of the demand for medical devices and drugs. In this context, an important shortage of programmable syringe pumps, used to administrate different drugs in intensive care units, was seen. The opportunity of administrating combinations of five intensive care units selected drugs (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine) was considered.
METHODS METHODS
The drug mixtures were studied in a pure form or diluted in NaCl 0.9% or G5%. Twenty-six possible combinations of the five drugs were produced in glass vials or polypropylene syringes and stored at 25 °C for 14 days. The LC method was implemented to study drugs combinations in the presence of the degradation products. The clearness and pH were also monitored.
RESULTS RESULTS
All the 26 possible combinations displayed adequate physicochemical stability at 25 °C: at least 3 days and 7 days, respectively, for the dilution in 0.9% NaCl or glucose 5%, and the pure drug products mixtures.
CONCLUSIONS CONCLUSIONS
The study provided sufficient stability results, covering the medication administration period of at least three days. The combination of more than two drugs offers the advantage of minimizing the individual doses and reduces unwanted side-effects. Hence, this study opens up the possibility of combining the five drugs in one single syringe, which is useful especially under the current circumstances associated with an important shortage of programmable syringe pumps and pharmaceuticals.

Identifiants

pubmed: 35335926
pii: pharmaceutics14030550
doi: 10.3390/pharmaceutics14030550
pmc: PMC8952813
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Pharm Weekbl Sci. 1992 Aug 21;14(4):196-200
pubmed: 1437499
Pharm Dev Technol. 2018 Dec;23(10):1067-1076
pubmed: 28990851
Drug Discov Today. 2016 Jul;21(7):1189-95
pubmed: 27240777
Can J Hosp Pharm. 2013 May;66(3):198
pubmed: 23814289
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
J Pain Symptom Manage. 2004 May;27(5):471-5
pubmed: 15120775
J Sep Sci. 2007 Aug;30(12):1833-8
pubmed: 17638356
J Pharm Biomed Anal. 2000 Aug 15;23(2-3):421-8
pubmed: 10933535
J Pharm Biomed Anal. 2015 Feb;105:74-83
pubmed: 25543285
Am J Health Syst Pharm. 2014 Apr 15;71(8):657-61
pubmed: 24688040
Eur J Pharm Sci. 2003 May;19(1):31-6
pubmed: 12729859
Am J Health Syst Pharm. 2011 Aug 15;68(16):1537-40
pubmed: 21817086

Auteurs

Maria Gloria Tarantini (MG)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.
Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Via Pietro Giuria, 11, 10125 Torino, Italy.

Stéphanie Ramos (S)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.
Matériaux et Santé, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Philippe-Henri Secrétan (PH)

Matériaux et Santé, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Laura Guichard (L)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.
Matériaux et Santé, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Lamia Hassani (L)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.

Agnès Bellanger (A)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.

Julien Mayaux (J)

Department of Pulmonology Intensive Care Medicine and Resuscitation, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.

Patrick Tilleul (P)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.
Faculty of Pharmacy, University of Paris-Descartes, 4 Avenue de l'Observatoire, 75006 Paris, France.

Fadwa El Kouari (F)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.

Hassane Sadou Yayé (H)

Department of Pharmacy, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris-Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.
Matériaux et Santé, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Classifications MeSH